Abstract
BackgroundIQOS was the first heated tobacco product to receive Food and Drug Administration (FDA) authorisation for ‘reduced exposure’ marketing claims, which has been exploited globally.MethodsIn November–December 2021, we conducted a survey-based 3×3 factorial experiment among US (n=1128) and Israeli adults (n=1094). We presented: (1) reduced exposure, reduced risk and control messaging and (2) 2 variations of FDA endorsement and control messaging. Each participant was randomly assigned to evaluate 2 ads (displayed on different ad imagery), then completed assessments of perceived relative harm, exposure and disease risk and likelihood of personally trying or suggesting IQOS to smokers. Ordinal logistic regression examined messaging conditions and their interactions, on the 5 outcomes, respectively, adjusting for covariates.ResultsControl (vs reduced exposure) messaging resulted in higher perceived relative harm (adjusted OR (aOR)=1.29, 95% CI=1.12 to 1.48), exposure (aOR=1.34, 95% CI=1.17 to 1.54) and disease risk (aOR=1.23; 95% CI=1.08 to 1.40), and lower likelihood of suggesting IQOS to smokers (aOR=0.85; 95% CI=0.74 to 0.97). Reduced risk (vs exposure) messaging resulted in lower perceived relative harm (aOR=0.86; 95% CI=0.75 to 0.99). One FDA endorsement message (‘IQOS (completed) the US FDA examination of tobacco products. FDA concluded that IQOS is a better choice for adult smokers’) was associated with greater likelihood of suggesting IQOS to smokers, relative to control (aOR=1.19; 95% CI=1.04 to 1.37). No interactions between risk/exposure messaging and FDA endorsement messaging were found. Additionally, Israeli participants, cigarette users and men perceived lower relative harm and exposure and greater likelihood of trying or suggesting IQOS to smokers.ConclusionsRegulators must monitor direct and indirect advertising content of modified risk tobacco product-authorised products and prevent potentially harmful misinterpretations.
Funder
Division of Cancer Prevention, National Cancer Institute
Subject
Public Health, Environmental and Occupational Health,Health (social science)
Reference59 articles.
1. Tobacco Control Legal Consortium . The FDA’s premarket review of tobacco products fails to fully protect public health. St. Paul, MN: Public Health Law Center, 2017.
2. US Food and Drug Administration, Marketing Order . FDA submission tracking numbers (STNs): PM0000424- PM0000426, PM0000479, IQOS system holder and Charger and Marlboro Heatsticks, 2019. Available: https://www.fda.gov/tobacco-products/premarket-tobacco-product-applications/premarket-tobacco-product-marketing-orders [Accessed 06 Aug 2020].
3. Ratajczak A , Jankowski P , Strus P , et al . Heat not burn tobacco product—a new global trend: impact of heat-not-burn tobacco products on public health, a systematic review. Int J Environ Res Public Health 2020;17:409.doi:10.3390/ijerph17020409
4. Informing iQOS regulations in the United States: a synthesis of what we know;Berg;Sage Open,2020
5. International PM . In how many countries do you sell your cigarette brands? 2020. Available: https://www.pmi.com/faq-section/faq/in-how-many-countries-do-you-sell-your-cigarette-brands#
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献